← Eichor
Condition: Recurrent Or Metastatic Nasopharyngeal Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Or Metastatic Nasopharyngeal Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06629597Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Tr
Phase 2 · 6 location(s) · Ming-Yuan Chen · NCT07070479Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06197776Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06657690Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Meta
Phase 2 · 88 location(s) · National Cancer Institute (NCI) · NCT06029270A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Phase 1/Phase 2 · 20 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07258979A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance
Phase 2 · 15 location(s) · Shanghai Henlius Biotech · NCT06839066Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic H
Phase 1 · 1 location(s) · West China Hospital · NCT07625423A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Me
Phase 3 · 1 location(s) · Shanghai Miracogen Inc. · NCT06976190Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Ming-Yuan Chen · NCT07581821A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcin
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06437522A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemothera
Phase 2/Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06241599Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objective
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT01365169Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
Phase 3 · 1 location(s) · Fudan University · NCT06177301Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous
Phase 1 · 2 location(s) · Emory University · NCT06868433Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi
NA · 1 location(s) · Emory University · NCT06662058The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Phase 2 · 3 location(s) · Chongqing University Cancer Hospital · NCT04830267Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Phase 2 · 1 location(s) · Ming-Yuan Chen · NCT06472713Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07101744Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 · 2 location(s) · Emory University · NCT06636734
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.